Diseases | Free Full-Text | Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia | HTML
Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials | DAIC
The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran (NASDAQ:MDCO) | Seeking Alpha
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender | Novartis
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol | NEJM
Dr. Martha Gulati “Get Vaccinated Please” på Twitter: "Clinical trials Phase III on ORION: Inclisiran vs placebo: 55% LDL reduction on top of lipid lowering therapy #ACC20 https://t.co/mhgNXuKyiJ" / Twitter
Cureus | Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
ESC 2019 – Medicines Company impresses with inclisiran | Evaluate
RNAi Inclisiran A Novel Approach to PCSK 9
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
Inclisiran - Lappin - 2021 - Practical Diabetes - Wiley Online Library
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug's Approval | tctmd.com
PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status - PACE-CME
AHA 2019 – The Medicines Company reaches for the stars | Evaluate
Abstract 13503: Relative Efficacy of Alirocumab, Bempedoic Acid, Evolocumab, Ezetimibe and Inclisiran Added to Statins for Reduction of Low Density Lipoprotein Cholesterol - A Network Meta-Analysis of Randomized Clinical Trials | Circulation
Inclisiran Reduced LDL-C in Obese Patients | DAIC
Inclisiran (siRNA) for the Treatment of Hypercholesterolemia: PDUFA Date Set as December 2020
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol | NEJM
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis | Journal of the American College of Cardiology
FAQ — ORION 4
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender | Novartis
